AlphAIAlphAI — Financial news for AI agents
healthandme.comOCT 232 min read$MRNA

World’s First Cancer Vaccine By Moderna & Merck Cuts Melanoma Recurrence Risk By 42%, Cancer Spread Risk By 38%

Moderna and Merck's personalized cancer vaccine, intismeran autogene, reduced melanoma recurrence or death risk by 42% and spread risk by 38% in a Phase 3 trial. The vaccine, combined with Merck's Keytruda, showed 82.2% cancer-free rate after two years. The companies plan to seek regulatory approval.

Original reporting
healthandme.com
Published Oct 23, 2026, 5:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 5:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$MRNA
Bullish
high confidence
Mentioned
$MRNA · $MRK
Relevance
9/10
AlphAI data visualization · based on healthandme.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The data could accelerate regulatory submissions and reshape oncology treatment strategies.

02

Market read

Both stocks may experience short-term price moves as investors digest the trial outcomes.

03

What to watch

Manufacturing scale-up costs and competition from other mRNA cancer therapies.

Relevance 9/10Novelty 9/10Timing: today

Background

First public disclosure of Phase 3 results for a personalized mRNA cancer vaccine by Moderna and Merck.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna's Phase 3 cancer vaccine trial showed a 42% reduction in melanoma recurrence risk, a first-time disclosure.

Expected impact

upward pressure as investors price in potential approval and market opportunity

Evidence & confidence

Phase 3 results are material for a biotech; market typically reacts strongly to such data.

$MRKBullishHigh confidence
Context

Merck's partner in the trial, its Keytruda combo showed significant benefit, newly reported.

Expected impact

moderate upside as the data expands Merck's immunotherapy portfolio

Evidence & confidence

Keytruda is a core product; new efficacy data can boost revenue outlook.

Market effects

Sector

Strengthens the oncology immunotherapy sector and validates mRNA vaccine platforms.

Regional

Potential uplift for US biotech indices and related ADRs.

Global

May influence global cancer treatment pipelines and attract international investors.

Counterpoint

What could challenge this read

Skeptics may question long-term durability of benefit and regulatory hurdles.

Key entities

  • Company
    Moderna

    Biotech firm developing the mRNA vaccine.

  • Company
    Merck

    Pharma partner providing Keytruda.

Read at source← All news

StoryModerna and Merck shares tumble after apparent leak of Phase 3 melanoma vaccine data

Also covered by

6 outlets

Related articles

OCT 23
$MRKHighAI 9/10

Merck, Moderna Personalized MRNA Caner Vaccine Cuts Melanoma Recurrence Risk In Phase 3 Study

Merck (MRK) and Moderna (MRNA) reported Phase 3 trial results showing their personalized mRNA cancer vaccine, intismeran, combined with KEYTRUDA, reduced melanoma recurrence risk by 42% vs. KEYTRUDA alone. The two-year recurrence-free survival rate was 82.2% for the combination vs. 70.0% for KEYTRUDA. The companies plan to discuss results with regulators and advance further studies. MRK stock closed at $147.24, down 1.76%.

rttnews.com2 min
OCT 23
$MRNAHigh

Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations

Moderna (MRNA) shares dropped 25% despite positive cancer vaccine data, which reduced melanoma recurrence or death risk by 42% in certain patients. The stock remains up 530% in 2026. Analysts attribute the selloff to high expectations. The vaccine, paired with Merck's Keytruda, showed 82% of patients alive without recurrence at two years. Full phase 3 results are pending.

finance.yahoo.com2 min
OCT 23
$MRNAHigh

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings

Moderna (MRNA) shares fell sharply, marking their worst week in three months. Analysts from Bernstein, TD Cowen, and BMO Capital Markets expressed mixed views on the company's cancer vaccine data, with price targets implying significant downside. Moderna reported a revenue decline in 2025 and aims for cash breakeven by 2028. Earnings are due on Nov. 6. Retail sentiment on Stocktwits remains bullish for both Moderna and Merck (MRK).

finance.yahoo.com2 min
OCT 23
$MRNAHighAI 8/10

Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says

Moderna (MRNA) shares fell 17.6% on Oct. 22 after Phase 3 trial results for its cancer vaccine were leaked. The drop occurred despite positive results for the vaccine, developed with Merck (MRK). Analysts attributed the decline to a 'sell the news' event, with Bernstein maintaining a $45 price target and Wells Fargo suggesting concerns may be overdone. Merck shares also dropped 1.76%.

finance.yahoo.com2 min
OCT 23
$MRNAHighAI 9/10

Moderna stock plunges 25% after melanoma vaccine data leak

Moderna (MRNA) stock fell 25.2% to $183.88 on 22 October 2026 after leaked Phase 3 trial data for its melanoma vaccine showed a 42% risk reduction, below investor expectations of 49%. The selloff erased $24bn in market value. Merck (MRK), Moderna's partner, dropped 1%. Analysts attributed the reaction to high expectations and a sell-the-news move.

financial-news.co.uk2 min